GlassScriptPhysician profile
Manish Khanna
NPI 1518008580
$24,071.56
in general payments reported to CMS, 2019-2025
24 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,054 · 2020: $834 · 2021: $823 · 2022: $6,933 · 2023: $6,626 · 2024: $6,264 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,000.00 |
| Food and Beverage | $1,427.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $18,745.83 | 2020-2025 | |
| Stryker Corporation | $2,432.46 | 2019-2023 | Xpress Ent Dilation System |
| Glaxosmithkline, LLC. | $544.47 | 2021-2025 | Nucala |
| Genzyme Corporation | $535.06 | 2020-2025 | |
| Intersect Ent, INC. | $394.66 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $222.13 | 2022-2025 | Dupixent |
| Medtronic USA, INC. | $170.94 | 2019 | |
| Xoran Technologies LLC | $153.33 | 2021 | |
| Acclarent, INC | $153.26 | 2019-2020 | |
| Alk-Abello, INC | $139.06 | 2022-2025 | Neffy, Grastek, Ragwitek |
| Medtronic, INC. | $131.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $83.19 | 2025 | Tezspire |
| Aerin Medical INC. | $80.73 | 2020-2025 | |
| Kaleo, INC. | $51.94 | 2019-2020 | |
| Phadia US INC. | $48.11 | 2019-2023 | Immunocap |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $27.26 | 2025 | Neffy |
| Uswm, LLC | $26.00 | 2021 | |
| Merck Sharp & Dohme LLC | $23.36 | 2023 | |
| Watermark Medical, INC. | $20.43 | 2024 | |
| Neurent Medical Limited | $19.98 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Paratek Pharmaceuticals, INC. | $19.33 | 2025 | Xhance, Nuzyra |
| Amgen INC. | $17.63 | 2025 | Tezspire |
| Kowa Pharmaceuticals America, INC. | $16.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.